- Home
- NRIM vs OLMA Comparison
NRIM vs OLMA Comparison
Compare NRIM & OLMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NRIM
- OLMA
- Stock Information
- Founded
- NRIM 1990
- OLMA 2006
- Country
- NRIM United States
- OLMA United States
- Employees
- NRIM N/A
- OLMA N/A
- Industry
- NRIM Savings Institutions
- OLMA Biotechnology: Pharmaceutical Preparations
- Sector
- NRIM Finance
- OLMA Health Care
- Exchange
- NRIM Nasdaq
- OLMA Nasdaq
- Market Cap
- NRIM 488.2M
- OLMA 560.7M
- IPO Year
- NRIM N/A
- OLMA 2020
- Fundamental
- Price
- NRIM $20.95
- OLMA $10.82
- Analyst Decision
- NRIM
- OLMA Strong Buy
- Analyst Count
- NRIM 0
- OLMA 6
- Target Price
- NRIM N/A
- OLMA $23.33
- AVG Volume (30 Days)
- NRIM 167.2K
- OLMA 1.2M
- Earning Date
- NRIM 10-22-2025
- OLMA 11-11-2025
- Dividend Yield
- NRIM 3.01%
- OLMA N/A
- EPS Growth
- NRIM 38.28
- OLMA N/A
- EPS
- NRIM 2.00
- OLMA N/A
- Revenue
- NRIM $175,041,000.00
- OLMA N/A
- Revenue This Year
- NRIM N/A
- OLMA N/A
- Revenue Next Year
- NRIM $8.63
- OLMA N/A
- P/E Ratio
- NRIM $10.65
- OLMA N/A
- Revenue Growth
- NRIM 28.34
- OLMA N/A
- 52 Week Low
- NRIM $15.92
- OLMA $2.86
- 52 Week High
- NRIM $25.05
- OLMA $13.51
- Technical
- Relative Strength Index (RSI)
- NRIM 12.12
- OLMA 69.51
- Support Level
- NRIM $21.10
- OLMA $10.24
- Resistance Level
- NRIM $22.22
- OLMA $11.54
- Average True Range (ATR)
- NRIM 0.55
- OLMA 0.76
- MACD
- NRIM -0.23
- OLMA 0.04
- Stochastic Oscillator
- NRIM 0.00
- OLMA 75.70
About NRIM Northrim BanCorp Inc
Northrim BanCorp Inc is a bank holding company. The Company operates in three reportable segments: Community Banking, Home Mortgage Lending, and Specialty Finance. It generates maximum revenue from the Community Banking segment which offers loan and deposit products to business and consumer customers in its market areas and operates nearly 20 branches throughout Alaska.
About OLMA Olema Pharmaceuticals Inc.
Olema Pharmaceuticals inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of next generation targeted therapies for women's cancers. Its therapies offer the potential to improve outcomes for women living with cancer. The company has completed discovery and preclinical studies of OP-1250. OP-3136 is another drug candidate in the company's product pipeline.